Robert D. Evans Sells 10,000 Shares of Penumbra, Inc. (NYSE:PEN) Stock
Penumbra, Inc. (NYSE:PEN) EVP Robert D. Evans sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $85.15, for a total value of $851,500.00. Following the completion of the transaction, the executive vice president now directly owns 11,704 shares in the company, valued at approximately $996,595.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Penumbra, Inc. (NYSE PEN) traded down 1.48% during trading on Friday, hitting $86.65. The company’s stock had a trading volume of 349,052 shares. Penumbra, Inc. has a one year low of $56.05 and a one year high of $91.00. The firm has a market cap of $2.93 billion, a PE ratio of 585.47 and a beta of 0.10. The company has a 50-day moving average of $85.47 and a 200 day moving average of $82.17.
Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Penumbra had a negative net margin of 2.78% and a negative return on equity of 2.58%. The company had revenue of $80.60 million during the quarter, compared to the consensus estimate of $77.16 million. During the same quarter in the prior year, the firm posted $0.01 earnings per share. Penumbra’s revenue for the quarter was up 23.8% on a year-over-year basis. On average, equities analysts forecast that Penumbra, Inc. will post ($0.21) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/robert-d-evans-sells-10000-shares-of-penumbra-inc-nysepen-stock.html.
Several large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Penumbra by 10.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock valued at $102,000 after buying an additional 114 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in shares of Penumbra during the first quarter valued at $194,000. Simplex Trading LLC increased its stake in shares of Penumbra by 11.5% in the first quarter. Simplex Trading LLC now owns 2,565 shares of the company’s stock valued at $214,000 after buying an additional 265 shares during the period. FNY Partners Fund LP acquired a new stake in shares of Penumbra during the first quarter valued at $223,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Penumbra during the second quarter valued at $252,000. Institutional investors and hedge funds own 69.01% of the company’s stock.
Several analysts have issued reports on PEN shares. BidaskClub cut Penumbra from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research cut Penumbra from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. Canaccord Genuity reaffirmed a “buy” rating and set a $94.00 target price on shares of Penumbra in a research report on Tuesday, June 13th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $96.00 target price on shares of Penumbra in a research report on Friday, June 16th.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.